Abstract
Context: Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results. Objective: To determine the clinical efficacy of GbE in mild to moderate dementia of the Alzheimer type. Design: Randomized, placebo-controlled, double-blind, parallel-group, multicenter trial. Setting: Outpatient clinics of universities and private research centers specialized in dementia. Patients: 513 outpatients with uncomplicated dementia of the Alzheimers type scoring 10 to 24 on the Mini-Mental State Examination and less than 4 on the modified Hachinski Ischemic Score, free of other serious illnesses and not requiring continuous treatment with any psychoactive drug. Intervention: 26-week treatment with GbE at daily doses of 120 mg or 240 mg or placebo. Main Outcomes: Cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog), Alzheimers Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC). Results: There were no significant between-group differences for the whole sample. There was little cognitive and functional decline of the placebo-treated patients, however. For a subgroup of patients with neuropsychiatric symptoms there was a greater decline of placebo-treated patients and significantly better cognitive performance and global assessment scores for the patients on GbE. Conclusion: The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. Thus, the study remains inconclusive with respect to the efficacy of GbE.
Keywords: Ginkgo biloba, dementia, Alzheimer's disease, treatment, randomized controlled trial
Current Alzheimer Research
Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type
Volume: 2 Issue: 5
Author(s): Lon S. Schneider, Steven T. DeKosky, Martin R. Farlow, Pierre N. Tariot, Robert Hoerr and Meinhard Kieser
Affiliation:
Keywords: Ginkgo biloba, dementia, Alzheimer's disease, treatment, randomized controlled trial
Abstract: Context: Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results. Objective: To determine the clinical efficacy of GbE in mild to moderate dementia of the Alzheimer type. Design: Randomized, placebo-controlled, double-blind, parallel-group, multicenter trial. Setting: Outpatient clinics of universities and private research centers specialized in dementia. Patients: 513 outpatients with uncomplicated dementia of the Alzheimers type scoring 10 to 24 on the Mini-Mental State Examination and less than 4 on the modified Hachinski Ischemic Score, free of other serious illnesses and not requiring continuous treatment with any psychoactive drug. Intervention: 26-week treatment with GbE at daily doses of 120 mg or 240 mg or placebo. Main Outcomes: Cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog), Alzheimers Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC). Results: There were no significant between-group differences for the whole sample. There was little cognitive and functional decline of the placebo-treated patients, however. For a subgroup of patients with neuropsychiatric symptoms there was a greater decline of placebo-treated patients and significantly better cognitive performance and global assessment scores for the patients on GbE. Conclusion: The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. Thus, the study remains inconclusive with respect to the efficacy of GbE.
Export Options
About this article
Cite this article as:
Schneider S. Lon, DeKosky T. Steven, Farlow R. Martin, Tariot N. Pierre, Hoerr Robert and Kieser Meinhard, A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type, Current Alzheimer Research 2005; 2 (5) . https://dx.doi.org/10.2174/156720505774932287
DOI https://dx.doi.org/10.2174/156720505774932287 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Consequences of Locus Coeruleus Degeneration in Alzheimers Disease
Current Alzheimer Research 5-HT6 Receptor Antagonists as Potential Therapeutics for Cognitive Impairment
Current Topics in Medicinal Chemistry Full Kinetics and a Mechanistic Investigation of the Synthesis of Tetrahydrobenzo[ b]pyrans in the Presence of Sodium Acetate as a Catalyst by a One-pot Three-component Reaction
Letters in Organic Chemistry Neuroprotector Effect of Daily 8-Minutes of High-Intensity Interval Training in Rat Aβ<sub>1-42</sub> Alzheimer Disease Model
Current Alzheimer Research An Introduction to Obesity and Dementia
Current Alzheimer Research Sensory-Motor Integration in the Medial Medulla
Current Neuropharmacology Bioinformatic Analysis of HIV-1 Entry and Pathogenesis
Current HIV Research Cognition and Neuropathology in Aging: Multidimensional Perspectives from the Rush Religious Orders Study and Rush Memory and Aging Project
Current Alzheimer Research Mental Training for Cognitive Improvement in Elderly People: What have We Learned from Clinical and Neurophysiologic Studies?
Current Alzheimer Research Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry The Cholinergic System: An Emerging Drug Target for Schizophrenia
Current Pharmaceutical Design Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Patents on Potential Drugs to Treat Alzheimer’s Disease: Special Emphasis on Small Peptides
Recent Patents on CNS Drug Discovery (Discontinued) Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Multi-potent Natural Scaffolds Targeting Amyloid Cascade: In Search of Alzheimer's Disease Therapeutics
Current Topics in Medicinal Chemistry Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Retraction Notice to Role of Vitamin K2 in the Treatment of Postmenopausal Osteoporosis
Current Drug Safety Neuroprotection Abilities of Cytosolic Phospholipase A2 Inhibitors in Kainic acid-induced Neurodegeneration
Current Drug Targets - Cardiovascular & Hematological Disorders Biological Evaluation of Halogenated Thioureas as Cholinesterases Inhibitors Against Alzheimer’s Disease & Molecular Modeling Studies
Letters in Drug Design & Discovery